Original Research
Published on 16 May 2024
Sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents ejection fraction reduction, reduces myocardial and renal NF-ÎşB expression and systemic pro-inflammatory biomarkers in models of short-term doxorubicin cardiotoxicity
in Cardio-Oncology
Frontiers in Cardiovascular Medicine
doi 10.3389/fcvm.2024.1289663
- 10,654 views
- 26 citations

